Literature DB >> 23801152

Effects of ARHI on breast cancer cell biological behavior regulated by microRNA-221.

Ying Li1, Mei Liu, Yanjun Zhang, Chun Han, Junhao You, Junlan Yang, Cheng Cao, Shunchang Jiao.   

Abstract

The aplysia ras homolog member I (ARHI) is a tumor suppressor gene and is downregulated in various cancers. The downregulation of ARHI was regulated by miR-221 in prostate cancer cell lines. However, it has not been reported whether ARHI is regulated by miR-221 in breast cancer. Here, we reported that the ARHI protein level was downregulated in breast cancer tissues and breast cancer cell lines. The overexpression of ARHI could inhibit cell proliferation and invasion and induce cell apoptosis. To address whether ARHI is regulated by miR-221 in breast cancer cell lines, the results in this study showed that a significant inverse correlation existed between ARHI and miR-221. MiR-221 displayed an upregulation in breast cancer tissues and breast cancer cell lines. The inhibition of miR-221 induced a significant upregulation of ARHI in MCF-7 cells. To prove a direct interaction between miR-221 and ARHI mRNA, ARHI 3'UTR, which includes the potential target site for miR-221, was cloned downstream of the luciferase reporter gene of the pMIR-REPORT vector to generate the pMIR-ARHI-3'UTR vector. The results confirmed a direct interaction of miR-221 with a target site on the 3'UTR of ARHI. In conclusion, ARHI is a tumor suppressor gene that is downregulated in breast cancer. The overexpression of ARHI could inhibit breast cancer cell proliferation and invasion and induce cell apoptosis. This study demonstrated for the first time that the downregulation of ARHI in breast cancer cells could be regulated by miR-221.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23801152     DOI: 10.1007/s13277-013-0933-6

Source DB:  PubMed          Journal:  Tumour Biol        ISSN: 1010-4283


  48 in total

1.  MicroRNAs and small interfering RNAs can inhibit mRNA expression by similar mechanisms.

Authors:  Yan Zeng; Rui Yi; Bryan R Cullen
Journal:  Proc Natl Acad Sci U S A       Date:  2003-08-05       Impact factor: 11.205

2.  MicroRNAs 221/222 and genistein-mediated regulation of ARHI tumor suppressor gene in prostate cancer.

Authors:  Yi Chen; Mohd Saif Zaman; Guoren Deng; Shahana Majid; Shranjot Saini; Jan Liu; Yuichiro Tanaka; Rajvir Dahiya
Journal:  Cancer Prev Res (Phila)       Date:  2010-11-11

3.  The therapeutic potential of microRNAs in cancer.

Authors:  Stine B Thorsen; Susanna Obad; Niels F Jensen; Jan Stenvang; Sakari Kauppinen
Journal:  Cancer J       Date:  2012 May-Jun       Impact factor: 3.360

4.  Proteomic studies in breast cancer (Review).

Authors:  Xian-Ju Qin; Bruce X Ling
Journal:  Oncol Lett       Date:  2012-01-18       Impact factor: 2.967

5.  miR-221/222 targeting of trichorhinophalangeal 1 (TRPS1) promotes epithelial-to-mesenchymal transition in breast cancer.

Authors:  Susanna Stinson; Mark R Lackner; Alex T Adai; Nancy Yu; Hyo-Jin Kim; Carol O'Brien; Jill Spoerke; Suchit Jhunjhunwala; Zachary Boyd; Thomas Januario; Robert J Newman; Peng Yue; Richard Bourgon; Zora Modrusan; Howard M Stern; Søren Warming; Frederic J de Sauvage; Lukas Amler; Ru-Fang Yeh; David Dornan
Journal:  Sci Signal       Date:  2011-08-09       Impact factor: 8.192

Review 6.  p27(Kip1) V109G polymorphism and cancer risk: a systematic review and meta-analysis.

Authors:  Feng Wei; Jin Xu; Lin Tang; Jiaqing Shao; Yucai Wang; Longbang Chen; Xiaoxiang Guan
Journal:  Cancer Biother Radiopharm       Date:  2012-07-23       Impact factor: 3.099

7.  Characterization of a novel cell line established from a patient with Herceptin-resistant breast cancer.

Authors:  Minna Tanner; Anita I Kapanen; Teemu Junttila; Olayinka Raheem; Seija Grenman; Jussi Elo; Klaus Elenius; Jorma Isola
Journal:  Mol Cancer Ther       Date:  2004-12       Impact factor: 6.261

8.  miR-221&222 regulate TRAIL resistance and enhance tumorigenicity through PTEN and TIMP3 downregulation.

Authors:  Michela Garofalo; Gianpiero Di Leva; Giulia Romano; Gerard Nuovo; Sung-Suk Suh; Apollinaire Ngankeu; Cristian Taccioli; Flavia Pichiorri; Hansjuerg Alder; Paola Secchiero; Pierluigi Gasparini; Arianna Gonelli; Stefan Costinean; Mario Acunzo; Gerolama Condorelli; Carlo Maria Croce
Journal:  Cancer Cell       Date:  2009-12-08       Impact factor: 31.743

9.  Breast cancer manifested by hematologic disorders.

Authors:  Takashi Ishikawa; Daisuke Shimizu; Ayako Kito; Ikuko Ota; Takeshi Sasaki; Mikiko Tanabe; Akimitsu Yamada; Hitoshi Arioka; Satoru Shimizu; Junichi Wakasugi; Ryutaro Mori; Takashi Chishima; Yasushi Ichikawa; Itaru Endo
Journal:  J Thorac Dis       Date:  2012-12       Impact factor: 2.895

10.  NOEY2 (ARHI), an imprinted putative tumor suppressor gene in ovarian and breast carcinomas.

Authors:  Y Yu; F Xu; H Peng; X Fang; S Zhao; Y Li; B Cuevas; W L Kuo; J W Gray; M Siciliano; G B Mills; R C Bast
Journal:  Proc Natl Acad Sci U S A       Date:  1999-01-05       Impact factor: 11.205

View more
  9 in total

1.  The role of aplysia ras homolog I in colon cancer cell invasion and adhesion.

Authors:  Jun Ouyang; Xiaohui Pan; Zecheng Hu
Journal:  Exp Ther Med       Date:  2017-09-18       Impact factor: 2.447

2.  RAS-related GTPases DIRAS1 and DIRAS2 induce autophagic cancer cell death and are required for autophagy in murine ovarian cancer cells.

Authors:  Margie N Sutton; Hailing Yang; Gilbert Y Huang; Caroline Fu; Michael Pontikos; Yan Wang; Weiqun Mao; Lan Pang; Maojie Yang; Jinsong Liu; Jan Parker-Thornburg; Zhen Lu; Robert C Bast
Journal:  Autophagy       Date:  2018-03-21       Impact factor: 16.016

Review 3.  Regulation of epithelial-mesenchymal transition through microRNAs: clinical and biological significance of microRNAs in breast cancer.

Authors:  Fu Peng; Liang Xiong; Hailin Tang; Cheng Peng; Jianping Chen
Journal:  Tumour Biol       Date:  2016-09-19

4.  Loss of ARHI expression in colon cancer and its clinical significance.

Authors:  Wei Wang; Lili Chen; Qun Tang; Yonggang Fan; Xiaoru Zhang; Jingming Zhai
Journal:  Contemp Oncol (Pozn)       Date:  2014-11-05

5.  Targeted Inhibition of miR-221/222 Promotes Cell Sensitivity to Cisplatin in Triple-Negative Breast Cancer MDA-MB-231 Cells.

Authors:  Shujun Li; Qun Li; Jinhui Lü; Qian Zhao; Danni Li; Lei Shen; Zhongrui Wang; Junjun Liu; Dongping Xie; William C Cho; Shaohua Xu; Zuoren Yu
Journal:  Front Genet       Date:  2020-01-14       Impact factor: 4.599

Review 6.  Exploring miRNA-Associated Signatures with Diagnostic Relevance in Glioblastoma Multiforme and Breast Cancer Patients.

Authors:  Véronique C LeBlanc; Pier Morin
Journal:  J Clin Med       Date:  2015-08-14       Impact factor: 4.241

7.  The effects of long-term daily folic acid and vitamin B12 supplementation on genome-wide DNA methylation in elderly subjects.

Authors:  Dieuwertje E G Kok; Rosalie A M Dhonukshe-Rutten; Carolien Lute; Sandra G Heil; André G Uitterlinden; Nathalie van der Velde; Joyce B J van Meurs; Natasja M van Schoor; Guido J E J Hooiveld; Lisette C P G M de Groot; Ellen Kampman; Wilma T Steegenga
Journal:  Clin Epigenetics       Date:  2015-11-14       Impact factor: 6.551

8.  JMJD2A contributes to breast cancer progression through transcriptional repression of the tumor suppressor ARHI.

Authors:  Li-Liang Li; Ai-Min Xue; Bei-Xu Li; Yi-Wen Shen; Yu-Hua Li; Cheng-Liang Luo; Ming-Chang Zhang; Jie-Qing Jiang; Zu-De Xu; Jian-Hui Xie; Zi-Qin Zhao
Journal:  Breast Cancer Res       Date:  2014-05-30       Impact factor: 6.466

Review 9.  The role of microRNAs in prostate cancer progression.

Authors:  U-Ging Lo; Diane Yang; Jer-Tsong Hsieh
Journal:  Transl Androl Urol       Date:  2013-09
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.